BioPharma Dive August 12, 2024
The company plans to present results from the Phase 3 MONeT trial at a scientific conference, as well as to submit them to regulatory agencies.
Dive Brief:
- Pfizer on Monday said its RSV vaccine Abrysvo led to strong immune responses in immunocompromised adults given the shot in a late-stage study.
- The results came from a substudy of a Pfizer-run Phase 3 trial testing two doses of Abrysvo in adults at risk of severe lower respiratory tract disease associated with respiratory syncytial virus, or RSV. Vaccination was well-tolerated, Pfizer said, and led to a “strong neutralizing response” against RSV subtypes A and B.
- The data add to evidence of the effectiveness of Abrysvo, which faces competition from GSK’s rival vaccine...
Today's Sponsors
Today's Sponsor